The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice

Non-alcoholic fatty liver disease (NAFLD), which is strongly associated with metabolic syndrome, is increasingly a major cause of hepatic disorder. Dipeptidyl peptidase (DPP)-4 inhibitors, anti-diabetic agents, are expected to be effective for the treatment of NAFLD. In the present study, we establi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ideta, Takayasu, Shirakami, Yohei, Miyazaki, Tsuneyuki, Kochi, Takahiro, Sakai, Hiroyasu, Moriwaki, Hisataka, Shimizu, Masahito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691103/
https://www.ncbi.nlm.nih.gov/pubmed/26670228
http://dx.doi.org/10.3390/ijms161226156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691103/
https://www.ncbi.nlm.nih.gov/pubmed/26670228
http://dx.doi.org/10.3390/ijms161226156

Ejemplares similares